The global Hematologic Malignancies market was valued at $42.8 Billion in 2017 and is forecast to grow at a modest XX.2 % CAGR between 2018 and 2025, culminating in 2025 global sales of $67.5 Billion.
There are no definitive causes for hematologic malignancies. These cells in hematologic cancers arise from types of white blood cells: lymphocytes, granulocytes, and plasma cells. Approximately one in every 3 minutes diagnosed with a blood cancer in U.S. 174,250 people in the US are expected to be diagnosed with leukemia, lymphoma or myeloma in 2018. New cases of leukemia, lymphoma, and myeloma are expected to account for 10 percent of the estimated 1,735,350 new cancer cases diagnosed in the US in 2018.
On an average every 9 minutes or 6 people every hour, in the US dies from a blood cancer. Leukemia, lymphoma, and myeloma are expected to cause the deaths of an estimated 58,100 people in the US in 2018. These account for 9.5 percent of the total deaths from cancer in 2018, based on the estimated total of 609,640 cancer deaths.
“Optimal Price Point (OPP) for Hematologic Malignancies Products”
Estimated Average product/ service cost – $ xx globally. However, with improving access and availability of options, OPP and range of acceptable Prices (RAP) are going to change. We at Ameri Research continuously track these prices with our proprietary pricing model.
Due to the wide array of products available in the market, pricing, positioning, and sales channel optimization play a vital role in the success of a product. On an average, in the U.S., the blood cancer drugs are available at USD xxx- USD xxxx. However, the high-end products are available at much higher prices. The prices in emerging countries and developed countries vary significantly due to the difference in purchasing power and availability of latest products.
Hematologic Malignancies Market by “Disease Type”
We have segmented the hematologic malignancies market into Leukemia, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Multiple Myeloma. Leukemia involves the creation of abnormal white blood cells (WBC’s). There is a different type of Leukemia as acute lymphocytic leukemia (ALL), acute myelogenous leukemia (AML), chronic lymphocytic leukemia (CLL), and chronic myelogenous leukemia (CML). Lymphoma is the type of hematologic malignancies involving lymphatic system. The major difference between Non-Hodgkin and Hodgkin lymphoma are Reed-Sternberg cells. Myeloma is hematologic malignancies in plasma cells help to create antibodies. We are observing a steep rise in Leukemia during forecasting period.
Hematologic Malignancies Market by “Treatment Categories”
We have segmented the hematologic malignancies market by treatment into Chemotherapy, Radiation therapy, Immunotherapy and Stem Cell Transplantation. We are observing newer biologic into immunotherapy shaping the hematologic malignancies. Advancing novel therapeutic agents for the treatment of malignancy proving costly and lengthy process. Cost estimates for de novo drug discovery range from $500 million to $2 billion.
Hematologic Malignancies Market by “Drug Class”
We have broadly segmented the market as Antineoplastic agent, Chemotherapy, Kinase Inhibitor and Others. Some of the major drugs, we have classified as Antineoplastic agent (Rituxan, Gleevec, Revlimid, Pomalyst, Vidaza, Kyprolis, Adcetris), Chemotherapy (Velcade), Kinase Inhibitor (Tasigna). Gleevec reported sales of USD 448 million in 2017.
Hematologic Malignancies Market by “Distribution Channel”
We have segmented the market based on distribution channel as Hospitals, Drug Store, Specialty Pharmacy, E-Pharmacy. Majority of products channelized through hospitals (Particularly Chemo, Surgery and Radiation). However, we are observing the increased role of specialized pharmacy and E-pharmacy in the distribution/ dispensation of treatment drugs. Patient education to increase compliance and Persistency plays a key role in the outcome. Many payors are linking reimbursement to the outcome.
North America accounted for the maximum revenue share of over 40% in 2017 due to increased patient number, lifestyle followed by availability of treatment options, better reimbursement plan, and RND. Followed by EU- Top 5 countries contribute $X.6 Billion in 2017 and expected to reach $x.5 Billion by 2023.
With changing lifestyle in developing countries and availability of treatment option, we are observing a rise in patient numbers in developing countries. However, these markets represent a minuscule percentage of the overall market.
“Competitive Landscape” and “Merger & Acquisition Insights”
The key market participants include Pfizer Inc., Novartis AG, F. Hoffmann-LA Roche Ltd, Celgene, Sanofi-Aventis, Bristol-Myers Squibb Company, AbbVie, GlaxoSmithKline, Amgen, Johnson & Johnson, and Takeda Pharmaceutical Company Limited. The growing investment in research and development is driving the companies to innovate, stay market relevant and retain their share. Moreover, there are several startup companies working on stem cell and biologic research, and these companies are considered as strategic assets for merger and acquisition. Some of the most notable transactions in the recent past include,
- Amgen to Acquire Micromet, which is working on a Novel Cancer Treatment in Clinical Trials for Hematologic Malignancies.
- Celgene reportedly in talks to buy CAR-T cell therapy firm.
Hematologic Malignancies Market by Disease Type (Revenue, Million, 2014 – 2025)
- Acute Lymphocytic Leukemia
- Chronic Lymphocytic Leukemia
- Acute Myeloid Leukemia
- Chronic Myeloid Leukemia
- Non-Hodgkin Lymphoma
- B-cell Lymphoma
- Diffuse Large B-Cell Lymphoma
- Mantle Cell Lymphoma
- Burkitt Lymphoma
- Central Nervous System Lymphoma
- T-cell Lymphoma
- Precursor T-Lymphoblastic Lymphoma
- Peripheral T-Lymphoma
- Hodgkin Lymphoma
- Multiple Myeloma
- B-cell Lymphoma
Hematologic Malignancies Market by Treatment Categories (Revenue, Million, 2014 – 2025)
- Radiation therapy
- Stem Cell Transplantation
Hematologic Malignancies Market by Drug Class (Revenue, Million, 2014 – 2025)
- Antineoplastic agent (Glivec, Revlimid (Lenalidomide), Pomalyst (Pomalidomide) Vidaza (Azacitidine) Kyprolis (Carfilzomib) Adcetris (Brentuximab Vedotin))
- Chemotherapy (Velcade (Bortezomib)
- Kinase Inhibitor (Tasigna (Nilotinib))
Hematologic Malignancies Market by Distribution Channel (Revenue, Million, 2014 – 2025)
- Drug Store
- Specialty Pharmacy
Hematologic Malignancies Market Regional Outlook (Revenue, USD Million, 2014- 2025)
- North America
- Asia Pacific
- Latin America
- Middle East and Africa
- South Africa
- Saudi Arabia
Hematologic Malignancies Market, Hematologic Malignancies Market Analytics, Hematologic Malignancies Market Share, Hematologic Malignancies Market Research, Hematologic Malignancies Market Forecast, Hematologic Malignancies Market Insight, Hematologic Malignancies Market Trend, Hematologic Malignancies Market Value,Hematologic Malignancies Market Size, Hematologic Malignancies Market Analysis, Hematologic Malignancies Market Survey, Blood Cancer Drugs Market, Blood Cancer Drugs Market Analytics, Blood Cancer Drugs Market Share, Blood Cancer Drugs Market Research, Blood Cancer Drugs Market Forecast, Blood Cancer Drugs Market Insight, Blood Cancer Drugs Market Trend, Blood Cancer Drugs Market Value,Blood Cancer Drugs Market Size, Blood Cancer Drugs Market Analysis, Blood Cancer Drugs Market Survey